Vaxil Bio Ltd. | Income Statement
Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
4.60
-
9.00
22.00
47.00
56
Gross Income
4.60
-
9.00
22.00
47.00
56
SG&A Expense
373.60
378.30
1,061.00
1,668.00
1,756.00
985
EBIT
378.20
378.30
1,070.00
1,709.00
1,803.00
1,041
Unusual Expense
55.10
75.50
-
2,840.00
-
-
Non Operating Income/Expense
-
-
3.00
-
5.00
-
Pretax Income
433.30
302.70
1,073.00
4,539.00
1,798.00
1,047
Income Tax
5.00
-
-
-
-
-
Consolidated Net Income
428.30
302.70
1,073.00
4,539.00
1,798.00
1,047
Net Income
428.30
302.70
1,073.00
4,539.00
1,798.00
1,047
Net Income After Extraordinaries
428.30
302.70
1,073.00
4,539.00
1,798.00
1,047
Net Income Available to Common
428.30
302.70
1,073.00
4,539.00
1,798.00
1,047
EPS (Basic)
0.42
0.14
0.08
0.12
0.04
0.01
Basic Shares Outstanding
951.80
3,204.20
12,381.50
39,410.40
50,355.50
85,139.20
EPS (Diluted)
0.45
0.09
0.09
0.12
0.04
0.01
Diluted Shares Outstanding
951.80
3,204.20
12,381.50
39,410.40
50,355.50
85,139.20
EBITDA
378.20
378.30
1,061.00
1,687.00
1,756.00
985
Other Operating Expense
-
-
-
19.00
-
-
Non-Operating Interest Income
0.00
-
-
10.00
-
-
About Vaxil Bio
View Profile
